Type B Oxazole Crystal Polymorph for Thermal Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing oxazole compounds used for inhibiting PDE4 activity lack sufficient stability, particularly thermal stability, which affects their efficacy as anti-inflammatory agents.
Innovation Solution
A novel crystal form of the oxazole compound, referred to as type B crystal, is produced by allowing the type A crystal to stand at elevated temperatures for an extended period, resulting in enhanced stability characterized by specific X-ray diffraction peaks, infrared absorption bands, and a higher melting point.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional oxazole compounds are used for PDE4 inhibition, then anti-inflammatory activity is achieved, but thermal stability is insufficient
Solution Approach 1:
The patent applies parameter changes by discovering and characterizing a new crystal form (Type B) with different physical parameters including higher melting point (75-90°C vs lower for Type A) and distinct X-ray diffraction pattern. This crystal form polymorphism resolves the contradiction by providing enhanced thermal stability while maintaining the PDE4 inhibitory activity, as evidenced by the specific diffraction peaks at 2θ values of 9.6±0.2, 19.1±0.2, and 21.2±0.2 degrees
Solution Approach 2:
The patent utilizes phase transitions by describing the conversion process from Type A crystal to Type B crystal through heating and standing at elevated temperatures. This polymorphic transition enables the material to achieve a more stable crystalline phase with improved thermal properties, directly addressing the stability issue while preserving the pharmacological activity
2Reliability
If Type A crystal is converted to Type B crystal by heating, then thermal stability is improved, but additional processing time is required
Solution Approach 1:
The patent applies preliminary action by providing a straightforward conversion protocol where Type A crystal is heated to 50-100°C and stood for 1-48 hours to obtain Type B crystal. This pre-established conversion method enables manufacturers to efficiently produce the more stable form without complex additional processing, balancing the time investment against the gained stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The type B crystal exhibits improved thermal stability and higher melting point, providing enhanced stability and efficacy as an anti-inflammatory agent, particularly effective in treating eczema and dermatitis.
Implementation Method 1
A novel crystal form of the oxazole compound, referred to as type B crystal, is produced by allowing the type A crystal to stand at elevated temperatures for an extended period
Implementation Method 2
the crystal has peaks at diffraction angles 2θ(°) of 9.6±0.2, 19.1±0.2, and 21.2±0.2 in an X-ray powder diffraction pattern measured using Cukα characteristic X-rays
Implementation Method 3
the crystal has infrared absorption bands at wavenumbers (cm−1) of 3380±5, 2980±5, 1651±2, 1501±2, 1258±2, 1121±2, and 754±2 in an infrared absorption spectrum measured by a potassium bromide disk method
Data Source
AI summary
Provided is a crystal of a specific oxazole compound that has specific inhibitory activity against PDE4, and that shows excellent stability. Specifically, provided is a crystal of an oxazole compound represented by formula (5)wherein the crystal has peaks at diffraction angles 2θ(°) of 9.6±0.2, 19.1±0.2, and 21.2±0.2 in an X-ray powder diffraction pattern measured using Cukα characteristic X-rays.